MS

Manvendra Singh

Active Director Director DIN 08345551
DIN 08345551 First appointment Jan 2019 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2019
Shareholding value •••• Premium profile

About Manvendra Singh

Data last updated:

Manvendra Singh is a Director at Sgs Pharmaceutical Pvt Ltd (since 2019). The company operates in Pharma. Sgs Pharmaceutical Pvt Ltd reported revenue of ₹58.96 Cr (FY 2024).

DIN 08345551
Primary Designation Director
Industry Pharma
First Appointment 30 Jan 2019
Oldest Company Age 25 yrs
Largest company Sgs Pharmaceutical Pvt Ltd · ₹58.96 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sgs Pharmaceutical Pvt Ltd U24239DL2001PTC110738
Director30 Jan 20192001₹58.96 Cr (FY 2024)Active

Board colleagues of Manvendra Singh

NameDINCompanyDesignation
Nimish Gupta01211133Sgs Pharmaceutical Pvt LtdDirector

Directorship timeline

Open interactive timeline →
Sgs Pharmaceutical Pvt Ltd
Premium access

Shareholding and investment profile for Manvendra Singh

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Manvendra Singh

Manvendra Singh currently holds 1 directorship: Sgs Pharmaceutical Pvt Ltd (Director, since 30 Jan 2019, revenue ₹58.96 Cr (FY 2024)).

Manvendra Singh was first appointed on 30 Jan 2019 as Director at Sgs Pharmaceutical Pvt Ltd.

The current boards of Manvendra Singh's companies include Nimish Gupta (Sgs Pharmaceutical Pvt Ltd).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available